---
title: "Immunic (IMUX) Gets a Buy from LifeSci Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286679219.md"
description: "LifeSci Capital's Sam Slutsky has maintained a Buy rating on Immunic (IMUX) with a price target of $56.00. Slutsky, who focuses on the Healthcare sector, has an average return of 43.2% and a 51.21% success rate on his stock recommendations. Previously, Roth MKM also assigned a Buy rating to Immunic with a price target of $19.00."
datetime: "2026-05-17T16:46:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286679219.md)
  - [en](https://longbridge.com/en/news/286679219.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286679219.md)
---

# Immunic (IMUX) Gets a Buy from LifeSci Capital

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunic, with a price target of $56.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Slutsky covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Abivax SA Sponsored ADR, and Palvella Therapeutics. According to TipRanks, Slutsky has an average return of 43.2% and a 51.21% success rate on recommended stocks.

In a report released on May 14, Roth MKM also assigned a Buy rating to the stock with a $19.00 price target.

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)